Description:
This study will evaluate the safety and disease control rate of the combination of
pembrolizumab plus low-dose interleukin-2 in patients who have either advanced melanoma or
renal cell cancer.
Title
- Brief Title: Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer
- Official Title: Low-dose Interleukin-2 and Pembrolizumab Among Patients With Metastatic Melanoma and Renal Cell Carcinoma
Clinical Trial IDs
- ORG STUDY ID:
18537
- NCT ID:
NCT03111901
Conditions
- Carcinoma, Renal Cell
- Melanoma
Interventions
Drug | Synonyms | Arms |
---|
Pembrolizumab | MK-3475, KEYTRUDA | Level -1 |
Interleukin-2 | IL-2 | Level -1 |
Purpose
This study will evaluate the safety and disease control rate of the combination of
pembrolizumab plus low-dose interleukin-2 in patients who have either advanced melanoma or
renal cell cancer.
Trial Arms
Name | Type | Description | Interventions |
---|
Level 1 | Experimental | Pembrolizumab (200 mg) administered intravenously (day 2 of cycle 1; day 1 of cycles 2 and beyond); Low dose-interleukin 2 (LD-IL2) 12 MIU/m2 administered subcutaneously (days 1-5 and 8-12 of each cycle); each cycle is 21 days. | - Pembrolizumab
- Interleukin-2
|
Level -1 | Experimental | Pembrolizumab (200 mg) administered intravenously (day 2 of cycle 1; day 1 of cycles 2 and beyond); Low dose-interleukin 2 (LD-IL2) 5 MIU/m2 administered subcutaneously (days 1-5 and 8-12 of each cycle); each cycle is 21 days. | - Pembrolizumab
- Interleukin-2
|
Eligibility Criteria
Main Inclusion Criteria
- Stage IV or unresectable stage III malignant melanoma or renal cell carcinoma.
- Melanoma
- Patients must have failed anti-PD-1/PD-L1 antibody therapy.
- Patients must have failed ipilimumab or be intolerant of ipilimumab and therefore
unable to receive ipilimumab.
- Patients may, but are not obligated, to have failed high- dose IL2.
- BRAF status must be known or unable to be performed. If the melanoma expresses a
BRAF mutation of V600E, V600K, or V600R patient must have received and progressed
through a BRAF inhibitor or have failed that therapy due to toxicity.
- Renal Cell Carcinoma
- Patients must have failed anti-PD-1/PD-L1 antibody therapy.
- Patients must have failed a VEGF pathway inhibitor and a second tyrosine kinase
inhibitor.
- Patients may, but are not obligated, to have failed high- dose IL2.
- Measurable disease based upon RECIST 1.1.
- Subjects with brain metastases will be eligible if the following are true:
- Subjects with ≤ 3 brain metastases
- All metastases are ≤ 3 cm
- All metastases have been treated and are asymptomatic
- Steroids are not required for management of the brain metastases
- All metastases have been stable for 1 month following treatment
- Subjects with > 3 brain metastases
- All metastases are ≤ 3 cm
- All metastases have been treated and are asymptomatic
- Steroids are not required for management of the brain metastases
- All metastases have been stable for 6 months following treatment
- Performance status: ECOG 0-1.
- Adequate organ function.
- Ability to provide informed consent.
Main Exclusion Criteria:
- Pregnancy
- Currently participating and receiving study therapy or has participated in a study of
an investigational agent and received study therapy or used an investigational device
within 4 weeks of the first dose of treatment.
- Has a diagnosis of primary or secondary immunodeficiency or is receiving systemic
steroid therapy or any other form of immunosuppressive therapy within 3 weeks prior to
the first dose of trial treatment. Replacement doses of steroids are permitted.
- Known history of active TB (Bacillus Tuberculosis)
- Hypersensitivity to pembrolizumab or any of its excipients.
- Known additional malignancies (exceptions DCIS or LCIS, basal cell carcinoma of the
skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has
undergone potentially curative therapy).
- Prior anti-cancer monoclonal antibody (mAb) within 3 weeks prior to study Day 1 or who
has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents
administered more than 3 weeks earlier.
- Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2
weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline)
from adverse events due to a previously administered agent.
- Known carcinomatous meningitis.
- Active autoimmune disease that has required systemic treatment in the past 2 years.
Patients may be eligible if they have the following autoimmune diseases: thyroiditis
or hypothyroidism, mild arthritis, diabetes, resolved hypophysitis, ulcerative colitis
after total abdominal colectomy.
- Active infection requiring systemic therapy.
- Known psychiatric or substance abuse disorders.
- Known history of Human Immunodeficiency Virus (HIV).
- Known active Hepatitis B virus (HBV) or Hepatitis C virus (HCV).
- Has received a live vaccine within 30 days of planned start of study therapy.
- Severe chronic pulmonary disease.
- Congestive heart failure, angina, or symptomatic cardiac arrhythmia or is classified
according to the New York Heart Association classification as having Class III or IV
heart disease.
- History of (non-infectious) pneumonitis that required steroids or current pneumonitis.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Safety: adverse event profile |
Time Frame: | up to 90 days post-treatment |
Safety Issue: | |
Description: | Obtain preliminary data on the safety of LD-IL2 with pembrolizumab |
Secondary Outcome Measures
Measure: | Progression free survival: metastatic melanoma |
Time Frame: | From first response (SD/PR/CR) to time of recurrence/progression or death from any cause, whichever occurs first, assessed for an estimated total of 120 months. |
Safety Issue: | |
Description: | Estimate progression-free survival defined as the duration of time from first response (SD/PR/CR) to time of recurrence/progression or death from any cause, whichever occurs first |
Measure: | Progression free survival: renal cell cancer |
Time Frame: | From first response (SD/PR/CR) to time of recurrence/progression or death from any cause, whichever occurs first, assessed for an estimated total of 120 months. |
Safety Issue: | |
Description: | Estimate progression-free survival defined as the duration of time from first response (SD/PR/CR) to time of recurrence/progression or death from any cause, whichever occurs first |
Details
Phase: | Phase 1/Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Withdrawn |
Lead Sponsor: | William Grosh, MD |
Trial Keywords
- pembrolizumab
- IL-2
- interleukin-2
- MK-3475
Last Updated
July 12, 2019